Sodium diethylcarbamodithioate trihydrate, ACS, 99.0%  (Synonyms: Ditiocarb sodium trihydrate, ACS, 99.0%)

Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% (Ditiocarb sodium trihydrate, ACS, 99.0%) is a copper reagent. The reaction with Cu²⁺ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer^[1][2][3].

Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% reacts with the Cu²⁺ solution giving a complex of copper diethyldithiocarbamate, which enhances the rate of cementation^[1]. Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% is an agent with strong antioxidant capacity and chelating activities^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% improves the depressed immune responses of newborn and aged mice. Sodium diethylcarbamodithioate trihydrate prevents cisplatin nephrotoxicity in animals without reducing the antitumor activity. In that AIDS model, Sodium diethylcarbamodithioate trihydrate, ACS, 99.0% reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

225.31

C₅H₁₆NNaO₃S₂

20624-25-3

CCN(C(S[Na])=S)CC.O.O.O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.

  [2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44.  [Content Brief]

  [3]. Dufour P, et al. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9-12.  [Content Brief]